Adcock Ingram Holdings

Adcock Ingram Holdings is a South African pharmaceutical company focused on developing, manufacturing, and distributing a wide range of healthcare products, including prescription drugs and consumer health solutions. Founded in South Africa, Adcock Ingram Holdings operates in the pharmaceutical sector, offering diverse healthcare solutions. The company has maintained a consistent business strategy focused on addressing healthcare needs, although specific pivots are not noted. Its headquarters is located in Johannesburg, South Africa.

Adcock Ingram has established a significant presence in the African market and is known for its commitment to health and wellness across various demographics. In July 2025, Natco Pharma Limited, a portfolio company Multiples Alternate Asset Management, acquired a minority stake of 35. 75% in Adcock Ingram Holdings for ZAR 3. 71 billion.

As part of the deal, Adcock Ingram set to delist from JSE and Bidvest Group will retain its stake of about 64. 25%. Financial terms of the transaction were not disclosed. Adcock Ingram specializes in the development, manufacturing, and distribution of a comprehensive range of healthcare products.

Its core offerings include prescription pharmaceuticals, over-the-counter medications, and consumer health products tailored to various therapeutic areas such as pain relief, infectious diseases, and chronic conditions. The company serves a broad customer base, including healthcare professionals, hospitals, pharmacies, and consumers, ensuring that its products meet the wellness needs of diverse populations, particularly in South Africa and select international markets. In the most recent fiscal year 2023, Adcock Ingram reported a revenue of ZAR 8. 89 billion and an EBITDA of  ZAR 1.

30 billion. The company generates revenue through direct sales to both healthcare institutions and retail channels, focusing on bulk orders from hospitals and pharmacies while maintaining partnerships with wholesalers and retailers to enhance product distribution. Adcock Ingram plans to expand its product offerings by launching new innovations aimed at addressing unmet healthcare needs. The company is also focusing on entering new markets across the African continent and potentially in select international regions by the end of 2025.

Funding from its recent capital raise will be strategically allocated to support R&D initiatives for product development and to bolster distribution capabilities in targeted expansion areas.